Microglia are the resident immune cells of the central nervous system, serving as the brain's primary defense mechanism. In neurodegenerative diseases, microglia undergo dramatic phenotypic transformations that can be either protective or pathogenic. This comparison page examines how microglia dysfunction manifests across Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and Huntington's disease (HD).
Microglia are the resident immune cells of the central nervous system, serving as the brain's primary defense mechanism. In neurodegenerative diseases, microglia undergo dramatic phenotypic transformations that can be either protective or pathogenic. This comparison page examines how microglia dysfunction manifests across Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and Huntington's disease (HD).
| Feature | Alzheimer's Disease | Parkinson's Disease | ALS | FTD | Huntington's Disease |
|---------|---------------------|---------------------|-----|-----|---------------------|
| Primary Microglia Phenotype | DAM (Disease-Associated Microglia) | Pre-DAM, chronic activation | Activated, inflammatory | TREM2-deficient, DAM-like | Hyper-ramified, primed |
| Key Trigger | Amyloid-beta, tau pathology | α-Synuclein, Lewy bodies | Motor neuron debris, TDP-43 | Progranulin, TDP-43 | Mutant huntingtin, striatal degeneration |
| TREM2 Status | Loss-of-function variants increase risk | Altered expression, reduced phagocytosis | Reduced, affects debris clearance | Haploinsufficiency, risk variants | Altered signaling |
| Phagocytic Capacity | Impaired, Aβ seeding defect | Reduced α-synuclein clearance | Defective, accumulates debris | Impaired | Variable |
| Inflammatory Profile | IL-1β, TNF-α, IL-6 dominant | Chronic, moderate inflammation | Severe, NF-κB activation | Moderate, TREM2-driven | Chronic low-grade |
| Metabolic State | Glycolysis defect, ATP loss | Mitochondrial dysfunction | Metabolic impairment | Altered | Dysregulated |
| Complement Activation | C1q, C3-mediated synapse loss | C1q involvement | C1q, C3 upregulation | Limited data | C1q activation |
| TREM2-APOE Axis | Central driver of DAM | Impaired signaling | Disrupted | Critical | Altered |
The discovery of DAM by Keren-Shaul et al. (2017) transformed our understanding of microglial involvement in neurodegeneration [1]. DAM follows a two-stage progression:
Microglia in AD display the most extensively characterized disease-associated phenotype:
Microglia in PD exhibit chronic activation patterns:
Microglia in ALS demonstrate particularly aggressive activation:
Microglial involvement in FTD varies by subtype:
Microglia in HD show distinctive changes:
The TREM2-APOE axis represents a convergent mechanism across all five diseases [3]. TREM2 loss-of-function impairs microglial metabolic fitness, phagocytosis, and survival. APOE4 variants exacerbate this dysfunction through reduced lipid efflux and increased inflammatory signaling.
Excessive complement activation (C1q, C3, C4) drives inappropriate synapse elimination in AD, PD, and ALS. This mechanism contributes to cognitive decline and disease progression.
All diseases feature microglial metabolic dysfunction, including impaired glycolysis, reduced ATP production, and mitochondrial dysfunction. The metabolic state directly influences inflammatory responses and phagocytic capacity.
Sustained production of pro-inflammatory cytokines (IL-1β, TNF-α, IL-6) creates a chronic neurotoxic environment across AD, PD, ALS, FTD, and HD.
| Target | Approach | Disease Relevance | Status |
|--------|----------|-------------------|--------|
| TREM2 Agonists | Activating antibodies, small molecules | AD (primary), PD, FTD | Phase II/III |
| TREM2 Modulation | Enhance ligand binding | All | Preclinical |
| CSF1R Inhibitors | Reduce microglial proliferation | ALS, PD | Phase I/II |
| CD33 Inhibitors | Block inhibitory signaling | AD | Preclinical |
| Complement Inhibitors | C1q, C3 blockade | AD, ALS, PD | Phase I/II |
| NLRP3 Inhibitors | Inflammasome blockade | AD, PD, ALS | Preclinical |
| CX3CR1 Modulation | Fractalkine pathway | PD, ALS | Preclinical |
| Metabolic Boosters | Glycolysis enhancement | All | Preclinical |
| Progranulin Enhancement | Increase TREM2 ligand | FTD, AD | Preclinical |
| Microglial Repopulation | PLX5622 + replacement | AD, PD, HD | Preclinical |
| NCT ID | Intervention | Target | Disease | Phase |
|--------|--------------|--------|---------|-------|
| NCT05164068 | PLX5622 | CSF1R | AD | Phase II |
| NCT04888966 | Pexidartinib (PLX3397) | CSF1R | PD | Phase I |
| NCT05037769 |AL002 | TREM2 Agonist | AD | Phase II |
| NCT04577382 | Anakinra | IL-1R | AD | Phase II |
| NCT05233735 | Bezafibrate | PPAR Agonist | ALS | Phase II |
| NCT04806061 | Eplonermin | CD95L | PD | Phase I |
| NCT05465606 | JAK1 Inhibitor | JAK/STAT | FTD | Phase I |
| NCT05481879 | Sotuletinib | CSF1R | HD | Phase I |
| Biomarker | Source | Disease | Significance |
|-----------|--------|---------|--------------|
| sTREM2 | CSF, blood | AD | Soluble TREM2, microglial activation |
| YKL-40 | CSF | AD, PD, ALS | Chitinase-3-like protein, inflammation |
| IL-1β | CSF, blood | All | Pro-inflammatory cytokine |
| TNF-α | CSF, blood | All | Inflammatory marker |
| GFAP | CSF, blood | All | Astrocyte activation (cross-talk) |
| Complement C1q | Brain tissue | AD, ALS, PD | Synapse pruning |
| CX3CL1 | CSF | PD | Fractalkine, microglial regulation |
| Gene | Function | Disease Association | Therapeutic Target |
|------|----------|---------------------|-------------------|
| TREM2 | Triggering receptor on myeloid cells 2 | AD risk variants (R47H), FTD haploinsufficiency | TREM2 agonists |
| APOE | Apolipoprotein E | AD (APOE4), modulates TREM2 | APOE modulators |
| CD33 | Siglec-3, inhibitory receptor | AD risk, modulates phagocytosis | CD33 inhibitors |
| CSF1R | Colony stimulating factor 1 receptor | Microglial proliferation | CSF1R antagonists |
| CX3CR1 | Fractalkine receptor | PD, ALS, modulates neuroinflammation | CX3CR1 modulators |
| NLRP3 | Inflammasome component | AD, PD, ALS | NLRP3 inhibitors |
| TYROBP | DAP12, TREM2 adaptor | AD, FTD | TREM2 pathway |
| C1QA | Complement C1q | AD, ALS, synapse pruning | C1q inhibitors |
| C3 | Complement C3 | AD, excessive pruning | C3 inhibitors |
| P2RY12 | Purinergic receptor | Homeostatic microglia marker | P2RY12 modulators |
| PROGRANULIN | Progranulin | FTD haploinsufficiency | Progranulin enhancers |
| GBA | Glucocerebrosidase | PD risk, lysosomal function | GBA modulators |